CAS: 1606974-33-7; 2-(4-((2-(3-Chlorophenyl)-6-(Trifluoromethyl)Pyridin-4-yl)Methyl)Phenyl)Acetic Acid

结构式图片

欧盟法规

C&L通报

上下游产品

Methyl 2-(4-((2-(3-Chlorophenyl)-6-(Trifluoromethyl)Pyridin-4-yl)Methyl)Phenyl)Acetate 1606974-32-6
4-Chloro-2-(3-Chlorophenyl)-6-(Trifluoromethyl)Pyridine 1606977-01-8

合成工艺路线路线简述

    📜4-(溴甲基)苯乙酸置于(1,1'-Bis(Diphenylphosphino)Ferrocene)Palladium(II) Dichloride,四(三苯基膦)钯,三甲基氯硅烷,Sodium Carbonate,Potassium Carbonate体系中,用 1,4-二氧六环,水 用作溶剂,化学反应 52.0H,反应生成4-[[2-(3-氯苯基)-6-(三氟甲基)-4-吡啶基]甲基]-苯乙酸
    参考文献: Heteroaryl Inhibitors Of Pde4[fr] Inhibiteurs Hétéroaryle De Pde4
    标题: Heteroaryl Inhibitors Of Pde4[fr] Inhibiteurs Hétéroaryle De Pde4

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: WHO Drug Information, Vol. 34, No. 2, 2020
    2: Ricciarelli R, Brullo C, Prickaerts J, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci Rep. 2017;7:46320. Published 2017 Apr 12. doi:10.1038/srep46320
    3: Gurney ME, Nugent RA, Mo X, et al. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. J Med Chem. 2019;62(10):4884-4901. doi:10.1021/acs.jmedchem.9b00193

    合成参考文献


    参考文献:10.1016/j.ejmech.2023.115195
    摘要:Li G, He D, Cai X, Guan W, Zhang Y, Wu J, Yao H. Advances in the development of phosphodiesterase-4 inhibitors. European Journal of Medicinal Chemistry. 2023 Mar;250():115195. doi: 10.1016/j.ejmech.2023.115195.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知